Cost-effectiveness of FDA variance for blood collection from individuals with hereditary hemochromatosis at a 398-bed hospital-based donor center

1.Leitman SF, Browning JN, Yau YY, et al. Hemochromatosis subjects as allogeneic blood donors; a prospective study. Transfusion 2003;43:1538–44.10.1046/j.1537-2995.2003.00570.x14617312Search in Google Scholar

2.Newman B. Hemochromatosis blood donor programs: marginal for the red blood cell supply but potentially good for patient care. Transfusion 2004;44:1537–8.10.1111/j.0041-1132.2004.00420_1.x15383032Search in Google Scholar

3.FDA Guidance. Variances for blood collection from individuals with hereditary hemochromatosis (HH). August 2001. Available at: (http://www.fda.gov/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/ Guidances/Blood/ucm076719.htm)Search in Google Scholar